Three common treatments and their possible links to aging and heart health
This review summarizes earlier studies on metformin, SGLT2 inhibitors, and fasting, and suggests a plan for using them together. It notes that key trials for fasting and for metformin in people without diabetes are missing.
Why artery aging may drive heart disease beyond cholesterol
This review pulls together recent and older studies on how aging blood vessels may fuel heart disease. It does not test a treatment, and it points to ideas still being studied.
Mitochondrial Quality Control in Degenerative Musculoskeletal Diseases: Signaling Networks and Therapeutic Landscapes.
Degenerative musculoskeletal disorders, including osteoarthritis (OA), intervertebral disc degeneration (IVDD), and osteoporosis (OP), are increasingly viewed as disorders of mitochondrial quality control (MQC) rather…
Metformin slowed frailty and lowered biological age in older adults
In a two-year trial, metformin slowed a frailty index score and lowered two blood-based aging clocks compared with placebo. The Fried frailty score showed no lasting difference once weight loss was removed, and the results do not show that metformin prevents frailty.
Metformin plus exercise and diet did not improve physical function in older adults with obesity
Researchers randomly assigned older adults with obesity to lifestyle changes, with or without metformin, or diet education with metformin. Adding metformin to intensive lifestyle changes did not improve physical function beyond lifestyle changes alone.